News related to Gamunex (Immune Globulin Intravenous Human) and/or conditions it is approved for
Nplate(TM) (Romiplostim) Receives Positive Opinion For Marketing Authorisation In The European Union
Source: Blood / Hematology News From Medical News Today [2008.11.28]
Amgen (Nasdaq: AMGN) announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for Nplate(TM) (romiplostim) in the European Union (EU). The CHMP recommends Nplate for adult chronic immune (idiopathic) thrombocytopenia purpura (ITP) splenectomised patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).
FDA Approves Promacta(R) (Eltrombopag), The First Oral Medication To Increase Platelet Production For People With Serious Blood Disorder
Source: Blood / Hematology News From Medical News Today [2008.11.22]
GlaxoSmithKline (NYSE: GSK) announced that the United States Food and Drug Administration (FDA) granted accelerated approval for PROMACTA(R) (eltrombopag) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.
|
